Relative to normal tissues, KDM1A in bladder cancer, colorectal cancer, kidney cancer, leukemia, and lung cancer was overexpressed, while it was downregulated in brain and CNS cancer and breast cancer, which made the potential function as either oncogenic or antitumor activities based on the cancer types. Here, KDM1A is linked to breast carcinoma.